BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33753248)

  • 1. Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis.
    Huang J; Zang Q; Wen Y; Pan Z; Yao Z; Huang M; Huang J; Chen J; Wang R
    Crit Rev Oncol Hematol; 2021 Apr; 160():103308. PubMed ID: 33753248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer.
    Renaud S; Guerrera F; Seitlinger J; Costardi L; Schaeffer M; Romain B; Mossetti C; Claire-Voegeli A; Filosso PL; Legrain M; Ruffini E; Falcoz PE; Oliaro A; Massard G
    Oncotarget; 2017 Jan; 8(2):2514-2524. PubMed ID: 27911859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
    Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
    Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
    Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
    Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.
    Renaud S; Romain B; Falcoz PE; Olland A; Santelmo N; Brigand C; Rohr S; Guenot D; Massard G
    Br J Cancer; 2015 Feb; 112(4):720-8. PubMed ID: 25688918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
    Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
    Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
    Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
    J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anatomical Resections Improve Survival Following Lung Metastasectomy of Colorectal Cancer Harboring KRAS Mutations.
    Renaud S; Seitlinger J; Lawati YA; Guerrera F; Falcoz PE; Massard G; Ferri L; Spicer J
    Ann Surg; 2019 Dec; 270(6):1170-1177. PubMed ID: 29781848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutations†.
    Renaud S; Schaeffer M; Falcoz PE; Seitlinger J; Romain B; Voegeli AC; Legrain M; Reeb J; Santelmo N; Rohr S; Brigand C; Olland A; Guenot D; Massard G
    Eur J Cardiothorac Surg; 2017 Feb; 51(2):255-262. PubMed ID: 28186237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis.
    Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Chang HJ; Kim HK; Joo KR; Lee JI
    Medicine (Baltimore); 2017 Sep; 96(35):e7882. PubMed ID: 28858102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS mutation: site of disease and recurrence pattern in colorectal cancer.
    Bonnot PE; Passot G
    Chin Clin Oncol; 2019 Oct; 8(5):55. PubMed ID: 31597436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy.
    Deboever N; Bayley EM; Eisenberg MA; Hofstetter WL; Mehran RJ; Rice DC; Rajaram R; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Bednarski BK; Morris VK; Antonoff MB
    J Thorac Cardiovasc Surg; 2024 Mar; 167(3):814-819.e2. PubMed ID: 37495170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
    Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
    Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
    J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.
    Osumi H; Shinozaki E; Suenaga M; Matsusaka S; Konishi T; Akiyoshi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Mise Y; Ishizawa T; Inoue Y; Takahashi Y; Saiura A; Uehara H; Mun M; Okumura S; Mizunuma N; Miki Y; Yamaguchi T
    Int J Cancer; 2016 Aug; 139(4):803-11. PubMed ID: 27004837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.
    Brudvik KW; Kopetz SE; Li L; Conrad C; Aloia TA; Vauthey JN
    Br J Surg; 2015 Sep; 102(10):1175-83. PubMed ID: 26206254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can we identify new biomarkers for patients with for lung metastasectomy in colorectal cancer.
    Renaud S; Falcoz PE
    Future Oncol; 2015; 11(15):2109-11. PubMed ID: 26235176
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
    Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
    J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.